Abstract
Gestational Trophoblastic Disease (GTD) includes a spectrum of interrelated pregnancy-associated diseases where abnormal growth disturbances of human trophoblast occur manifesting a wide range of biologic behaviour. More than 80% of GTD cases are benign in nature, though all have potentiality for malignant transformation of any magnitude. As a neoplastic disease, GTD is derived from foetal tissue, but exclusively invades maternal tissue. Production of large quantities of hCG is a hallmark. Spontaneous regression is possible—less in Choriocarcinoma. Because of haematogenous spread—it mimics good number of other pathologic conditions. This is the first disseminated solid tumour to be cured by Chemotherapy. Five clinico-pathological forms of GTD are recognised:
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lurain JR. Gestational trophoblastic disease: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease and management of hydatidiform mole. AM J Obstet Gynecol. 2010;203:531–9.
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717–29.
Ngan HY, Benders H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S. FIGO 2000 staging and classification. Int J Gynecol Obstet. 2003;83:175–7.
Wang Q, Fu J, Hu L, Fang F, Xie L, Chen H, He F, Wu T, Lawrie TA. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;9:Art. No.: CD007289.
Ngan HY, Seckl MJ, Berkowitz SR, Xiang Y, Sekharan PK, et al. “Update on the diagnosis and management of gestational trophoblastic disease.” FIGO CANCER REPORT. Int J Gynecol Obstet. 2018;143(Suppl. 2):79–85.
Hammond CB, Borchert LG, Tyrey L, et al. Treatment of metastatic disease; good and poor prognosis. Am J Obstet Gynecol. 1973;115:451–7.
Osborne RJ, Filiac VL, Schink JC, Mannel RS, Behbakhi K, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol. 2016 Sept;128(3):535–42.
Reda H, Elvira LV, Basem EL-D, Mahammad A, Eman T, et al. Second uterine curettage and number of chemotherapy courses in post molar gestational trophoblastic neoplasia. Obstet Gynecol. 2019;133(5):1024–31.
Froeling FEM, Seckl MJ. Uktra high risk gestational trophoblastic neoplasia. TB Gyn Oncol. 2018:1016–20.
Santaballa A, Garcıa Y, Herrero A, et al. SEOM clinical guidelines in gestational trophoblastic disease (2017). Clin Transl Oncol. 2018;20:38–46.
Tidy J, Seckl M, Hancock BW, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of Gestational Trophoblastic Disease. BJOG 2020.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Giri, S.K. (2021). Gestational Trophoblastic Disease: An Overview. In: Nayak, B., Singh, U. (eds) Gestational Trophoblastic Disease. Springer, Singapore. https://doi.org/10.1007/978-981-33-4878-3_1
Download citation
DOI: https://doi.org/10.1007/978-981-33-4878-3_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-33-4877-6
Online ISBN: 978-981-33-4878-3
eBook Packages: MedicineMedicine (R0)